MwanzoAMGN34 • BVMF
add
Amgen Inc. BDR
Bei iliyotangulia
R$ 52.95
Bei za siku
R$ 52.95 - R$ 53.35
Bei za mwaka
R$ 51.81 - R$ 73.92
Thamani ya kampuni katika soko
148.80B USD
Wastani wa hisa zilizouzwa
359.00
Uwiano wa bei na mapato
-
Mgao wa faida
-
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 9.18B | 9.43% |
Matumizi ya uendeshaji wa biashara | 3.50B | 12.82% |
Mapato halisi | 1.43B | 91.96% |
Kiwango cha faida halisi | 15.60 | 75.48% |
Mapato kwa kila hisa | 6.02 | 21.13% |
EBITDA | 4.34B | 5.79% |
Asilimia ya kodi ya mapato | 8.67% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 8.03B | -13.69% |
Jumla ya mali | 87.90B | -3.31% |
Jumla ya dhima | 80.47B | -5.31% |
Jumla ya hisa | 7.43B | — |
hisa zilizosalia | 538.36M | — |
Uwiano wa bei na thamani | 3.84 | — |
Faida inayotokana na mali | 8.47% | — |
Faida inayotokana mtaji | 11.81% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 1.43B | 91.96% |
Pesa kutokana na shughuli | 2.28B | -7.28% |
Pesa kutokana na uwekezaji | -389.00M | -79.26% |
Pesa kutokana na ufadhili | -2.67B | -0.91% |
Mabadiliko halisi ya pesa taslimu | -782.00M | -92.14% |
Mtiririko huru wa pesa | 220.75M | -92.64% |
Kuhusu
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp to stimulate erythropoiesis.
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.
The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health.
The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
8 Apr 1980
Makao Makuu
Tovuti
Wafanyakazi
28,000
